Evidence map›Paper›PMID 23890524›Full record

ArticleBioorganic & medicinal chemistry2013

Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.

Ramesh Alleti, Josef Vagner, Dilani Chathurika Dehigaspitiya, Valerie E Moberg, N G R D Elshan, Narges K Tafreshi, Nabila Brabez, Craig S Weber, Ronald M Lynch, Victor J Hruby and 3 more

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Biochimica et biophysica acta. Molecular basis of disease · 2017
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ramesh AlletiDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721-0041, USA.
Josef Vagner
Dilani Chathurika Dehigaspitiya
Valerie E Moberg
N G R D Elshan
Narges K Tafreshi
Nabila Brabez
Craig S Weber
Ronald M Lynch
Victor J Hruby
Robert J Gillies
David L Morse
Eugene A Mash
University of Arizona · USMoffitt Cancer Center · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Multimeric Ligands for Targeting of MelanomaR01CA097360 · NCI · UNIVERSITY OF ARIZONA · PI HRUBY, VICTOR J, MORSE, DAVID L · 2003 to 2012
$5.5M
Targeting Pancreatic CancerR01CA123547 · NCI · UNIVERSITY OF ARIZONA · PI MORSE, DAVID L · 2007 to 2011
$3.0M
Multimeric Ligands for Targeting of Pancreatic CancerR33CA095944 · NCI · UNIVERSITY OF ARIZONA · PI GILLIES, ROBERT J. · 2003 to 2005
$1.6M
NCI NIH HHS P30 CA023074NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA 23074NCI NIH HHS R01 CA097360NCI NIH HHS R01 CA 123547NCI NIH HHS R01 CA123547NCI NIH HHS R01 CA 97360NCI NIH HHS R33 CA095944NCI NIH HHS R33 CA 95944
6 · The paper itself

Abstract

Probes for use in time-resolved fluorescence competitive binding assays at melanocortin receptors based on the parental ligands MSH(4), MSH(7), and NDP-α-MSH were prepared by solid phase synthesis methods, purified, and characterized. The saturation binding of these probes was studied using HEK-293 cells engineered to overexpress the human melanocortin 4 receptor (hMC4R) as well as the human cholecystokinin 2 receptor (hCCK2R). The ratios of non-specific binding to total binding approached unity at high concentrations for each probe. At low probe concentrations, receptor-mediated binding and uptake was discernable, and so probe concentrations were kept as low as possible in determining Kd values. The Eu-DTPA-PEGO-MSH(4) probe exhibited low specific binding relative to non-specific binding, even at low nanomolar concentrations, and was deemed unsuitable for use in competition binding assays. The Eu-DTPA-PEGO probes based on MSH(7) and NDP-α-MSH exhibited Kd values of 27±3.9nM and 4.2±0.48nM, respectively, for binding with hMC4R. These probes were employed in competitive binding assays to characterize the interactions of hMC4R with monovalent and divalent MSH(4), MSH(7), and NDP-α-MSH constructs derived from squalene. Results from assays with both probes reflected only statistical enhancements, suggesting improper ligand spacing on the squalene scaffold for the divalent constructs. The Ki values from competitive binding assays that employed the MSH(7)-based probe were generally lower than the Ki values obtained when the probe based on NDP-α-MSH was employed, which is consistent with the greater potency of the latter probe. The probe based on MSH(7) was also competed with monovalent, divalent, and trivalent MSH(4) constructs that previously demonstrated multivalent binding in competitive binding assays against a variant of the probe based on NDP-α-MSH. Results from these assays confirm multivalent binding, but suggest a more modest increase in avidity for these MSH(4) constructs than was previously reported.

Indexed as

Binding, CompetitiveFluorescent DyesHEK293 CellsHumansPentetic AcidPeptidesProtein BindingReceptor, Cholecystokinin BReceptor, Melanocortin, Type 4Receptors, MelanocortinSolid-Phase Synthesis TechniquesFluorescent DyesMC4R protein, humanPentetic AcidPeptidesReceptor, Cholecystokinin BReceptor, Melanocortin, Type 4Receptors, Melanocortin19-amino-5-oxo-3,10,13,16-tetraoxa-6-azanonadecan-1-oic acid1-(9H-fluoren-9-yl)-3,19-dioxo-2,8,11,14,21-pentaoxa-4,18-diazatricosan-23-oic acid1-hydroxybenzotriazole6-chloro-1-hydroxybenzotriazole9-fluorenylmethyoxycarbonylAc-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH(2)bovine serum albuminBSACl-HOBtCompetition binding assayscopper(I)-catalyzed azide-alkyne cycloadditionCuAACDCMDICdichloromethaneDIEAdiethylenetriaminepentaacetic aciddiisopropyl carbodiimidediisopropylethylaminedimethyl sulfoxideDMEMDMFDMSODTPADulbecco’s Modified Eagle Mediumelectrospray ionization mass spectrometryESI MSFluorescent probesFmocFmoc-PEGOFourier transform ion cyclotron resonance mass spectrometryFT-ICR MShalf maximal inhibitory concentrationhigh resolution mass spectroscopyHis-DPhe-Arg-TrphMC4RHOBtHRMShuman melanocortin 4 receptorIC(50)Melanocortin 4 receptorMEMMinimum Essential MediumMSH(4)MSH(7)NDP-α-MSHN,N-dimethylformamidePEGOSaturation binding assaysSer-Nle-Glu-His-DPhe-Arg-TrpTBTATEAAtetrahydrofuranTFATHFthin-layer chromatographytime-resolved fluorescenceTime-resolved fluorescenceTLCTRFtriethylammonium acetatetrifluoroacetic acidtris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine

Identifiers

PMID23890524
PMCPMC3773999
OpenAlexW2159830221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.